The global pyrogen testing market is expected to grow at a CAGR of 12.7 percent from USD 927 million in 2020 to USD 1,689 million in 2025. The growing focus on customised medicine, increased R&D in the pharmaceutical and biotechnology industries, rising prevalence of chronic diseases, increased awareness of food safety, and rising incidence of infectious diseases and pandemics are all driving market expansion.
COVID-19 Impact on Global Pyrogen Testing Market
COVID-19 is a newly identified novel coronavirus that causes an infectious sickness. COVID-19, which was mostly unknown until the outbreak in Wuhan, China, in December 2019, has gone from a regional issue to a global pandemic in just a few weeks. Since the World Health Organization (WHO) proclaimed COVID-19 to be a pandemic, a number of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped up to create medicines and vaccines to combat the infection caused by the novel coronavirus. According to the WHO, there are currently 70 vaccine candidates in development, with three of them being studied in human trials. The economic and social costs of the pandemic have spurred governments around the world to increase funding for vaccine development, resulting in a rise in the use of pyrogen testing kits in COVID-19 research. Bacterial endotoxin testing will be an important quality assurance measure to ensure patient safety as vaccine manufacturing is likely to grow owing to COVID-19.
Market Dynamics
Infectious illness outbreaks are becoming more common, and pandemics are becoming more common.
Because of the rising prevalence of major infectious diseases and epidemics, the demand for pyrogen testing procedures has been steadily increasing over the last decade. During the projection period, demand for pyrogen testing procedures (used for endotoxin and microbial identification) is predicted to rise due to an increase in the global incidence of infectious diseases. Endotoxin identification products can help with infectious illness management, especially in countries where healthcare infrastructure is lacking.
Opportunity: Emerging markets are ripe for the picking.
The APAC region is a highly profitable market for the life sciences industry. For example, India has been taking substantial steps to promote itself as the world's leading major biopharmaceutical innovation hub, including fostering public-private partnerships (PPPs) in biopharmaceutical R&D projects. South Korea is likewise working to establish itself as a worldwide biotech center, focusing on biosimilars, vaccine development, and stem cell therapies. The growing need for rehabilitative treatments for life-threatening diseases like cancer and diabetes underscores the necessity for medication research and development, and thus the demand for pyrogen testing kits for effective quality testing and management.
Consolidation: High level of restraint
Pyrogen testing is a highly consolidated market. In 2019, the main companies in the pyrogen testing market—Charles River Laboratories, Inc. (US), Lonza (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), and Associates of Cape Cod, Inc. (US)—held a combined 75% market share. There is fierce competition among market participants. Only huge corporations can afford significant capital expenditures as well as high R&D and manufacturing costs. This will also deter new participants from entering the market. Furthermore, the market's top players are substantial and well-established, with a high level of brand loyalty.
Comments
Post a Comment